Skip to main content
. Author manuscript; available in PMC: 2011 May 2.
Published in final edited form as: Cancer. 2008 Nov 1;113(9):2478–2487. doi: 10.1002/cncr.23864

Table 3.

PSA Levels among Patients Discontinuing the Study

Region Treatment Group Mean PSA (ng/mL)
N Penultimate Visit Last Visit Increase

US Atrasentan 75 29.2 41.7 12.5
Placebo 61 36.8 53.2 16.4

Non-US Atrasentan 61 65.9 86.1 20.3
Placebo 50 79.6 98.2 18.6